425: Kintara Therapeutics Urges Stockholders to Vote on Proposed Merger with TuHURA Biosciences

Kintara Therapeutics is reminding stockholders to vote by September 19, 2024, to approve the proposed merger with TuHURA Biosciences.

Summary

• Kintara Therapeutics is urging its stockholders to vote in favor of the proposed merger with TuHURA Biosciences at the Special Meeting of Stockholders on September 20, 2024.
• The company emphasizes that a 'FOR' vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara's outstanding shares as of August 14, 2024, is required for the merger to proceed.
• Proposals 3 & 5 involve increasing the number of authorized shares and reincorporating Kintara from Nevada to Delaware, respectively.
• Kintara highlights that prominent proxy advisory services, Institutional Shareholder Services and Glass Lewis, have recommended stockholders vote 'FOR' Proposals 3 & 5.
• The merger aims to combine oncology assets and technologies to accelerate the pipeline, supported by $31 million in financing.
• Failure to complete the merger would leave Kintara's future uncertain.

Sentiment

Score: 5

Explanation: The document conveys a neutral sentiment, focusing on the importance of the stockholder vote for the proposed merger. While the potential benefits of the merger are highlighted, the uncertainty surrounding Kintara's future if the merger fails tempers the overall sentiment.

Positives

• The proposed merger with TuHURA Biosciences could accelerate Kintara's pipeline by combining oncology assets and technologies.
• The merger is supported by $31 million in financing.
• Prominent proxy advisory services recommend stockholders vote in favor of the merger.

Negatives

• The merger requires approval of Proposals 3 & 5 by a majority of voting power of outstanding shares as of August 14, 2024, and the voting threshold has not yet been reached.
• Failure to complete the merger would leave Kintara's future uncertain.

Risks

• The merger is contingent on stockholder approval and satisfaction of other closing conditions.
• There are risks related to estimating operating expenses and the impact of delays on cash resources.
• The announcement or pendency of the merger could affect Kintara's business relationships and operating results.
• Legal proceedings related to the merger could arise.
• The combined business of TuHURA and Kintara may not be successful.
• The company's future is uncertain if the merger is not completed.

Future Outlook

The company believes the merger will allow them to combine oncology assets and technologies to overcome treatment resistance and accelerate their pipeline. The future of Kintara is uncertain if the merger is not completed.

Management Comments

• Robert E. Hoffman, Kintara's Chief Executive Officer, stated, 'Your vote is crucial to our future and our mission to combat solid tumor cancers. By merging with TuHURA, we believe we can combine our oncology assets and technologies to overcome treatment resistance and accelerate our pipeline, backed by $31 million in financing. If the proposed Merger is not completed, the future of Kintara is uncertain.'

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate assets and expertise to accelerate drug development and overcome treatment resistance in cancer therapies.

Comparison to Industry Standards

• TuHURA's lead product candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors, similar to approaches being pursued by companies like Bristol-Myers Squibb and Merck.
• TuHURA is preparing to initiate a planned single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma, similar to trials being conducted by other companies in the immuno-oncology space.
• Kintara's REM-001 Therapy for cutaneous metastatic breast cancer (CMBC) has shown 80% complete responses of CMBC evaluable lesions, which is a competitive efficacy rate compared to other localized tumor treatments.

Stakeholder Impact

• Shareholders are urged to vote on the proposed merger, which could impact the value of their investment.
• Employees of both Kintara and TuHURA may be affected by the merger, depending on the integration plans.
• Patients with cancer could benefit from the combined company's accelerated pipeline of therapies.

Next Steps

• Stockholders need to vote on Proposals 3 & 5 by September 19, 2024.
• The Special Meeting of Stockholders will be held on September 20, 2024.
• Kintara and TuHURA will continue to work towards satisfying the conditions for closing the merger.

Key Dates